New 5-ylidene rhodanine derivatives based on the dispacamide A model

Abstract

(ProQuest: ... denotes formulae and/or non-USASCII text omitted; see image)

A practical approach for the preparation of (......) 5-ylidene rhodanine derivatives bearing the (4,5-dihalogeno-pyrrol-2-yl)carbamoyl fragment of dispacamide A is reported. The new compounds were obtained in good yields (19-88 %) by Knoevenagel condensation according to a solution-phase microwave dielectric heating protocol in the presence of organic bases (piperidine, TEA, and AcONa) from a set of ......-substituted rhodanines 2(a-i). The ten synthetic products 3(a-j) have been synthesized with a ......-geometry about their exocyclic double bond and the structure of one of these compounds (3) was confirmed by a single X-ray diffraction analysis. The new (......) 5-ylidene rhodanine derivatives 3(a-j) were tested against eight protein kinases.

[Figure not available: see fulltext.][PUBLICATION ABSTRACT]

Mol Divers (2014) 18:375388 DOI 10.1007/s11030-014-9509-7

FULL-LENGTH PAPER

New 5-ylidene rhodanine derivatives based on the dispacamide A model

Solene Guiheneuf Ludovic Paquin

Franois Carreaux Emilie Durieu Thierry Roisnel

Laurent Meijer Jean-Pierre Bazureau

Received: 26 September 2013 / Accepted: 4 February 2014 / Published online: 2 March 2014 Springer International Publishing Switzerland 2014

Abstract A practical approach for the preparation of (5Z) 5-ylidene rhodanine derivatives bearing the (4,5-dihalogeno-pyrrol-2-yl)carbamoyl fragment of dispacamide A is reported. The new compounds were obtained in good yields (1988%) by Knoevenagel condensation according to a solution-phase microwave dielectric heating protocol in the presence of organic bases (piperidine, TEA, and AcONa) from a set of N-substituted rhodanines 2(ai). The ten synthetic products 3(aj) have been synthesized with a Z-geometry about their exocyclic double bond and the structure of one of these compounds (3) was conrmed by a single X-ray diffraction analysis. The new (5Z) 5-ylidene rhodanine derivatives 3(aj) were tested against eight protein kinases.

Electronic supplementary material The online version of this article (doi:http://dx.doi.org/10.1007/s11030-014-9509-7

Web End =10.1007/s11030-014-9509-7 ) contains supplementary material, which is available to authorized users.

S. Guiheneuf L. Paquin F. Carreaux J.-P. Bazureau (B)

Universit de Rennes 1 Institut des Sciences Chimiques de Rennes ISCR UMR CNRS 6226, groupe Ingnierie Chimique et Molcules pour le Vivant (ICMV), Bt. 10 A, Campus de Beaulieu, CS 74205, 263 Avenue du Gnral Leclerc, 35042 Rennes Cedex, France e-mail: [email protected]

E. DurieuStation Biologique CNRS, Protein Phosphorylation & Human Disease, USR 3151, Place Georges Teissier, CS 90074, 29688 Roscoff Cedex, France

T. RoisnelUniversit de Rennes 1, Institut des Sciences Chimiques de Rennes ISCR UMR CNRS 6226, Centre de Diffractomtrie X (cdifx), Bt. 10 B, Campus de Beaulieu, CS 74205, 263 Avenue du Gnral Leclerc, 35042 Rennes Cedex, France

L. MeijerManRos Therapeutics (from Sea to Pharmacy), Htel de Recherche, Centre de Perharidy, 29680 Roscoff, France

Keywords Rhodanine 5-Ylidene rhodanine

Knoevenagel condensation Microwave condensation

2-Thioxo-imidazoline-4-one Kinase

Introduction

During the two last decades, the 5-arylidene-2-thioxothiazolidine-4-ones and 5-arylidene rhodanine derivatives have been the subject of intensive research by organic chemists and biologists because such compounds represent privileged scaffolds in drug discovery. A survey of recent literature showed that these compounds display a wide range of pharmaceutical properties. For example, epalrestat I (Fig. 1) was used in the treatment of diabetic peripheral neuropathy [1] and has been evaluated as aldose reductase inhibitor [2]. The 5-benzylidene rhodanine core (compound II) has been shown to inhibit the pancreatic cholesterol esterase [3] (CEase). A series of dimeric analogs based on BH3I [4] have been developed as small-molecule Bcl-2 antagonists (compounds III) for apoptosis through a complete SAR study [5]. To discover chemical probes to further understand the function of human DNA polymerase in cancer by high-throughput screening (HTS) using SYBR Green-based assay [6] and three 5-arylidene-2-thioxo-thiazolidine-4-ones (compounds IV) were identied as potent inhibitors. For Alzheimers disease, compounds containing the 5-arylidene rhodanine moiety are reported to have an inhibitory effect (compounds V) of tau aggregation [7], amyloid polypeptide bril formation [8,9], regulation of cathepsin-D immuno-reactivity (compound VI) in the senile plaques [10,11]. In addition, rhodanine-based molecules have become a popular small-molecule family of inhibitors for numerus targets in malaria [12,13], Hepatitis C [14], HIV infection [15,16],

123

376 Mol Divers (2014) 18:375388

R1

O CO2H

S

I

S

IV (R1 = NO2, Br, MeO; R2 = Me, F, Br)

S N

O H

N

S N

S NH

S

O

O CO2H

S

III (X = Br, Cl, H)

S

O

X

R2

N H

O

S NH

O

II

O

S

CO2H

O

O

S N

O

S

HO2C

O

O

S N

R

H N

Cl

HN

N

V

O

VI

VII

O

Fig. 1 Structures of some bioactive 5-arylidene rhodanine derivatives (IVI) and leucettine L41 (VII)

Fig. 2 N-3-substituted 5-ylidene rhodanine derivatives based on dispacamide A model

2-amino imidazolin-4-one platform

rhodanine platform

Br

NH2

O

S

O

X

N

S

Br NH

X N

R

N H

N H

O

H N

O

H N

Dispacamide A

New 5-ylidene rhodanines derivatives

obstructive pulmonary disease and asthma [17], anthrax and botulinum [18].

Our group, during the last 10 years, has investigated the chemical development of analogs of marine sponge alkaloid as inhibitors of protein kinases. Protein kinases represented a class of enzymes, which catalyze protein phosphorylation, a key cellular regulatory mechanism that is frequently deregulated in human diseases. We have recently identied the marine sponge alkaloid leucettamine B as an inhibitor of DYRKs/CLKs [19,20]. The synthesis of analogs of leucettamine B named leucettines (leucettine L41 VII) and the biological characterization of leucettines [21] showed that this family of kinase inhibitors deserves futher optimization as potential therapeutics against neurodegenerative diseases such as Alzheimers diseases [22,23]. In parallel, the 2-amino imidazoline-4-one moiety present in the marine sponge alkaloid dispacamide A (Fig. 1) [24] represented also an attractive scaffold for the search of potential new inhibitor of protein kinases. Recently, we have developed an efcient approach to dispacamide A and its analogs [25] in seven steps with an overall yield ranging from 12 to 33%. Unfortunately, the preliminary biological screening results of these new dispacamide A derivatives [26] showed moderate inhibition activities against serine/threonine kinases. In our efforts to discover new low molecular weight inhibitors of disease-relevant protein kinases, we focused now our attention on the synthesis of N-3-substituted 5-ylidene rhodanine derivatives based on dispacamide A model (Fig. 2). In this context, the 2-amino-

imidazoline-4-one platform of dispacamide A was replaced by a rhodanine platform.

In this approach, the planned retrosynthesis of these 5-ylidene rhodanine derivatives is based around the key aldol condensation between the N-(4,5-dihalogeno pyrrol-2-yl) carbamoyl aldehyde building-block and various 2-thioxo-thiazolidine-4-ones. This route was envisaged to be amenable to the design of new 5-ylidene rhodanine derivatives for their preliminary screening as kinase inhibitors. Our goal in this study is the development of a convenient, high yielding and robust reaction protocol for the preparation of new N-3-substituted 5-yliden-2-thioxo-thiazolidine-4-one derivatives.

Results and discussion

The overall strategy to the target 5-ylidene Nsubstituted

rhodanine derivatives is outlined in Scheme 1. For this study, we have examined the reactivity of various 2-thioxothiazolidine-4-ones 2(ai) with the N-(4,5-dihalogeno pyrrol-2-yl) carbamoyl aldehydes 1(a,b) in Knvenagel condensation under microwave dielectric heating. For the synthesis of small molecules with potential biological activity, the use of microwave irradiation is growing in importance [27,28] because the major benets of performing reaction under microwave irradiation are higher product yields and shorter reaction times as compared to reactions which run with conventional heating (i.e., in oil bath). A key advan-

123

Mol Divers (2014) 18:375388 377

catalyst, solvent (EtOH or AcOH, or AcOEt)

MWI,,70-150 C. 20-30 min.

X

X

X N

CCl3

N H

X S N

S

O

S

O

S

R

R

N H

O

O

HN O

N H

O

H N

2-trichloroacetyl pyrrole

3 steps

1(a,b): X = Cl, Br 3(a-j): X = Cl, Br

2(a-i)

O

O

S NH

S

O

S N

S

O

S N

S

O

CO2H S N

S

O

S N

S

O

CO2H

NH2

N

S

H

S N

S

O

R

2(a-i)

2a

2b

2c

2d

2e

O

O

O

O

S N

S

O

S N

O S N

N

S

O

N

S N

S

O

N

S

O

N

H

H

H

H

2f

2g

2h

2i

Scheme 1 General synthetic approach for 5-ylidene rhodanines derivatives 3(aj) and structure of the starting rhodanines 2(ai)

Scheme 2 Synthetic approachused for the preparation ofN-substituted rhodanines 2c,2(ei) Br

CO2H

CS2

KOH aq. 22%

i) 25 C, 3 hrsii) pH 4, 16hrs 2c

S N

S

O

CO2H

H2N

CO2H

-alanine

O

O

S

HN NH2

O O

HO2C S S CO2H

S H2O

95 C, 22 hrs

S N

S

S

O

N

H

2e

O

S

O

O THF

or PhMe

50-60 C, 2-23 hrs

R1

S N

NH2

2d

R1

Cl

S N

S

O

N

H 2(f-i)

tage of modern commercial scientic laboratory microwave apparatus is their ability to control reaction conditions precisely, by monitoring temperature/pressure, and reaction times.

The N-(4,5-dihalogeno pyrrol-2-yl) carbamoyl aldehyde partners 1(a,b) were prepared in three steps according to our previously published method [24]. Starting from commercial readily available 2-trichloroacetyl pyrrole, a regioselective halogenation was conducted by addition of bromine (X = Br) or sulfuryl chloride (X = Cl) to give the corresponding C-4, C-5 dihalogeno pyrroles (7090%), which were then coupled with 3,3-diethoxy-1-aminopropane (7588%). The corresponding N-(4,5-dihalogenopyrrol-2-yl) carbamoyl acetals were deprotected with p-TsOH at 55 C after 6h (98%) and led to the aldehyde building-blocks 1(a,b) in good overall yields (1a 60% for X = Br; 1b 66% for X = Cl).

For the present study, we have investigated the chemical reactivity of a series of various N-substituted rhodanines 2(ai) for Knoevenagel condensation in the presence of alde-

hydes 1(a,b). Among these compounds, rhodanine 2a, 2-(4-oxo-2-thioxo-thiazolidin-3-yl)acetic acid 2b and 3-amino rhodanine 2d are commercially available. Access to 3-(4-oxo-2-thioxo-thiazolidin-3-yl)propanoic acid 2c (Scheme 2) could be accomplished by the reaction of -alanine with carbon disulde and bromoacetic acid in aqueous potassium hydroxide [29]. After 3 h at room temperature, the reaction mixture was acidied at pH 4 and the desired insoluble compound 2c was obtained in 44% yield (Table 1) by simple ltration. To introduce the arylsulfonamide functionality on the rhodanine moiety in compound 2e, we used the Powers approach [14]: rstly, the formation of the arylsulfonyl hydrazide was accomplished by treatment of sulfonyl chloride at 0 C with hydrazine in THF followed by aqueous work-up and, secondly, the arylsulfonyl hydrazide treated with bis-(carbomethyl)trithiocarbonate [30,31] in water at 95 C for 22 h produced 3-(arylsulfonylamino)rhodanine 2e in 41% yield after purication by crystallization from ethanol.

123

378 Mol Divers (2014) 18:375388

Table 1 Results for the preparation of N-substituted rhodanines 2c, 2(ei)

Compound Structure Yielda (%) Compound Structure Yielda (%)

2c 44 2g 98

S N

S

O

O

CO2H S N

S

O

O

N

H

2e 41 2h 98

S N

S

O

O

O

O

S N

S

O

N

S

H

N

H

2f 90 2i 84

S N

S

O

O

O

N

S N

H

S

O

N

H

a Isolated yields after purication

Next, the preparation of compounds 2(fi) involved the use of commercial 3-amino rhodanine 2d as starting product. Among the conditions studied, we found that reaction of 2d with benzoyl chloride in THF at 60 C gave good conversion to 2f (90%) after 2 h. For compounds 2(gi), optimal reaction conditions were obtained only in dry toluene at 50 C. After a reaction time ranging from 8 (for 2g, h) to 23 h (for 2i) which were monitored by thin-layer chromatography on silica gel using dichloromethane/ethanol (9:1) as eluent, we obtained the crystallized compounds 2(gi) in good to high yields (8498%). With the desired N-substituted rhodanines 2(ai) and the N-(4,5-dihalogeno pyrrol-2-yl)carbamoyl aldehydes 1(a, b) in hand, we proceeded to examine the Knoevenagel condensation under microwave dielectric heating for the synthesis of new 5-ylidene rhodanines 3(aj) based on the dispacamide A model. In literature, the condensation of an aryl aldehyde to 2-thioxo-thiazolidine-4-one required the presence of a base such as piperidine in ethanol [32,33], piperi-dine/AcOH in ethanol under microwave irradiation [3437] or with a catalytic amount of piperidinium acetate in reuxing toluene [38], AcONa in reuxed AcOH [39,40] or concentrated ammonia solution in the presence of NH4Cl [41]. The use of solventless reaction conditions has also been employed with task specic ionic liquids (TSILs) [42,43] or with a solid inorganic support (Al2O3 or KSF) under microwave [44]. In this context, we decided to perform the condensation reaction under microwave dielectric heating and we screened a range of reaction parameters in order to nd optimal reaction conditions. Reaction optimization for the synthesis of compounds 3(aj) consisted of varying the reaction temperature (70150 C), the irradiation power (50200W), the reaction time (2040 min), the nature of the solvent (EtOH, AcOH, or

AcOEt), the base (piperidine, Et3N or AcONa) and the ratio of rhodanine 2 with the base. The reactions were conducted in borosilicate vials of 10 mL equipped with snap caps (at the end of the irradiation reaction time, cooling was realized automatically by compressed air). As shown in Table 2, the use of 0.1 equivalent of piperidine/AcOH in ethanol has been employed for the synthesis of N-3-substituted 5-ylidene rhodanine derivatives 3(ac) and3f in poor (3f 19%), moderate (3c 46%) to good yields (3a 88% and 3b 82%). In contrast, any effort to obtain Knoevenagel condensation adducts from the reaction of the other N-substituted rhodanines 2 with aldehydes 1(a, b) was unsuccessful using these reaction conditions. This implies that new specic synthetic protocols has to be devised for the others products 3. Finally, treatment of 1 and 2 with a stoichiometric mixture of AcONa/AcOH (1 equivalent) during 20 min at 120140 C afforded the compounds 3d and 3(gj) in yields ranging from 46 to 74%.

It is noteworthy that access to compound 3e required the use of triethylamine (TEA) in glacial acetic acid instead of piperidine or AcONa and the condensation reaction was conducted in ethyl acetate (AcOEt). Compound 3e was synthesized in 71% yield after a reaction time of 30 min using moderate reaction temperature (70 C) and irradiation power(50 W) in a glass vial without snap caps (or in open vessel at atmospheric pressure).

Structures of the desired compounds 3(aj) were substantiated by 1H, 13C NMR and HRMS analyses. In theory, E and Z geometrical isomers around the exocyclic double (CH=C) are possible for the N-3-substituted 5-ylidene rhodanine derivatives 3(aj). 1H NMR spectra of these compounds 3 show only one signal for the methylene proton (CH=) in the range of 6.827.20 ppm, at lower eld val-

123

Mol Divers (2014) 18:375388 379

Table 2 Results for the preparation of N-3-substituted 5-ylidene rhodanine derivatives 3(aj) from N-substituted rhodanines 2(ai) and 4,5-dihalogeno-1H-pyrrole-2-carboxylic acid (3-oxopropyl)-amide 1(a, b)

Compound Structure of compound 3

Reaction conditions used under microwavea Yieldb (%)

Reagents Solvent reaction

Reac. temp. (C)

Reac. time (min)

Power(W)

3a piperidine/AcOH (0.1 eq.) EtOH 150 20 200c 88

O

H N

Br

S

S

O

Br NH

N H

3b piperidine/AcOH (0.1 eq.) EtOH 150 20 200c 82

O

H N

Cl

S

S

O

Cl NH

N H

3c piperidine/AcOH (0.1 eq.) EtOH 110 40 d 46

O

H N

Br

S

S

O

Br N

N H

CO2H

3d AcONa/AcOH 1 eq. AcOH 140 20 60c 46

O

H N

Br

S

S

O

Br N

N H

CO2H

3e Et3N /AcOH (0.1 eq.) AcOEt 70 30 50c,e 71

O

H N

Br

S

S

O

Br N

NH2

N H

3f piperidine /AcOH (0.1 eq.) EtOH 150 20 d 19

O

H N

Br

O

O

S

S

O

S

Br N

N

H

N H

3g AcONa /AcOH (1 eq.) AcOH 120 20 100c 52

O

H N

Br

O

S

S

O

Br N

N

H

N H

3h AcONa /AcOH (1 eq.) AcOH 120 20 100c 74

O

H N

Br

O

S

S

O

O

Br N

N

H

N H

3i AcONa /AcOH (1 eq.) AcOH 120 20 100c 58

O

H N

Br

O

S

S

O

Br N

N

H

N H

3j AcONa /AcOH (1 eq.) AcOH 120 20 100c 49

O

H N

Br

O

S

S

O

Br N

N

H

N H

a Microwave irradiation of the reaction mixture was realized in a glass tube sealed with a snap cap (closed vessel)

b Isolated yield after workup and purication by preparative chromatography (on a Combi Flash R f 200 psi, Serlabo Technologies France using pre-packed column of silica gel 60 F 254 Merck equipped with a DAD UV/Vis 200360 nm detector) unless indicated otherwise

c Explorer24 (CEM France) used as microwave reactor

d Monowave300 (Anton Paar France) used as microwave reactor

e The reaction was conducted in glass tube without snap cap (open vessel mode)

ues than those expected for the E-isomers, which strongly indicates that the compounds have the Z-conguration. The Z-conguration of compounds 3(aj)was conrmed from

the 1H-coupled 13C NMR spectrum of these compounds followed by examination of the splitting pattern and coupling constant of the signal of the C=O group in the rhodanine sys-

123

380 Mol Divers (2014) 18:375388

Fig. 3 Ortep diagram of 4,5-dibromo-1H-pyrrol-2-carboxylic acid [3-(4-oxo-2-thioxo-thiazolidin-5-ylidene)-propyl]-amide 3a obtained by X-ray diffraction

Table 3 Effects of compounds 3(aj) on the catalytic activity of eight puried protein kinasesa

Compound CDK1 CDK2 CDK5/p25 GSK3/ CK1 DYRK1A CLK1

Dispacamide A >10 >10

3a >10 >10 >10 5.7

3b >10 >10 >10 >10 >10 >10 >10

3(cj)

a Compounds were tested at various concentrations on each kinase as described in Experimental section. IC50 values are reported in M, inactive at the highest concentration tested (10 M); >10 inhibitory but IC50 >10 M

tem [45]. Finally, the Z-conguration and also the chemical structure of 3 were conrmed by the single X-ray diffraction analysis of 4,5-dibromo-1H-pyrrol-2-carboxylic acid [3-(4-oxo-2-thioxo-thiazolidin-5-ylidene)-propyl]-amide 3a (Fig. 3).

As an initial effort to investigate their in vitro bioactivity, the new 5-ylidene rhodanine derivatives 3(aj) were tested against three protein kinases relevant to Alzheimers disease, CK1/ (casein kinase 1/), CDK5 (cyclin-dependent kinase 5)/p25 and GSK-3/ glycogen synthase kinase 3/. All assays were run in the presence of 15 M ATP and appropriate protein substrates (RRKHAAIGpSAYSITA peptide for CK1/, histone H1 for CDK5/p25, GS-1 (YRRAAVPPSPSLSRHSSPHQSpEDEEE) peptide for GSK-3/). IC50 values were determined from dose

response curves and are provided in Table 3.

These results are summarized in Table 3. The unsubstituted compound 3a showed promising inhibitory activity against DYRK1A with IC50 value in the single-digit micro-

molar range (3a: IC50 5.7 M). Yet the other new 5-ylidene rhodanine derivatives 3(cj) substituted in position N-3 were considered inactive on CDKs, GSK3/,CK1, CLK1 and DYRK1A since they displayed IC50 values above 10 M, these results suggested that these structures cannot be accommodated in the ATP binding site of these protein kinases by hydrogen bond interactions with specic amino-acids of the ATP-binding pocket of each protein kinase.

Conclusion

In summary, the present study described a practical approach to new 5-ylidene rhodanine derivatives 3(aj) bearing the (4,5-dihalogeno-pyrrol-2-yl)carbamoyl fragment of dispacamide A as potential inhibitors of protein kinases for therapeutics against neurodegenerative diseases. The key step of this solution phase organic synthesis involved a Knoevenagel condensation under microwave dielectric heat-

123

Mol Divers (2014) 18:375388 381

ing from N-(4,5-dihalogeno-pyrrol-2-yl) carbamoyl aldehydes 1(a, b) and N-substituted rhodanines 2(ai) partners.This microwave-assisted condensation afforded new (5Z) 5-ylidene rhodanines derivatives in a stereo-controlled fashion with yields ranging from 19 to 88% and in high purity after purication by preparative chromatography on silica gel.This work should enable further biological evaluations, new analogs though the simple synthetic process described here, and further studies towards a complete structureactivity relationship (SAR). These studies are on going in our laboratory.

Chemistry experimental part

Melting points were determined on a Koer melting point apparatus and were uncorrected. Thin-layer chromatography (TLC) was accomplished on 0.2-mm precoated plates of silica gel 60 F-254 (Merck). Visualization was made with ultraviolet light (254 and 365 nm) or with a uorescence indicator. 1H NMR spectra were recorded on BRUKER AC 300 P (300 MHz) spectrometer, 13C NMR spectra on BRUKER AC 300 P (75 MHz) spectrometer. Chemical shifts are expressed in parts per million downeld from tetramethylsilane as an internal standard. Data are given in the following order: value, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad), number of protons, coupling constants J is given in Hz. The mass spectra (HRMS) were taken respectively on a MS/MS ZAB-Spec Tof Micromass (EBE TOF geometry) at an ionizing potential of 8 eV and on a VARIAN MAT 311 at an ionizing potential of 70 eV in the Centre Rgional de Mesures Physiques de lOuest (CRMPO, Rennes). Reactions under microwave irradiations were realized in the Explorer24 CEM microwave reactor (CEM France) and also in the Anton Paar Monowave 300microwave reactor (Anton Paar France) using borosilicate glass vials of 10 mL equipped with snap caps (at the end of the irradiation, cooling reaction was realized by compressed air). The microwave instrument consists of a continuous focused microwave power output from 0 to 300 W for the Explorer24 CEM apparatus and from 0 to 800 W for the Anton Paar Monowave 300apparatus. All the experiments were performed using stirring option. The target temperature was reached with a ramp of 2 min and the chosen microwave power stay constant to hold the mixture at this temperature. The reaction temperature is monitored using calibrated infrared sensor and the reaction time included the ramp period. The microwave irradiation parameters (power and temperature) were monitored by the ChemDriver software package for the Explorer24 CEM apparatus and by the Monowave software package for the Anton Paar Monowave 300reactor. Preparative chromatographies were realized on a Combi Flash R f 200 psi (Serlabo Technologies France) using pre-packed column of

silica gel 60 F 254 Merck equipped with a DAD UV/Vis 200360 nm detector. Elemental analyses were performed on a Flash Microanalyzer EA1112 CHNS/O Thermo Electron in the Centre Rgional de Mesures Physiques de lOuest (CRMPO, Rennes). Solvents were evaporated with a BUCHI rotary evaporator. All reagents and solvents were purchased from Acros, Aldrich Chimie, and Fluka France and were used without further purication. The starting aldehydes 4,5-dibromo-1H-pyrrole-2-carboxylic acid (3-oxo-propyl)-amide 1a and 4,5-dichloro-1H-pyrrole-2-carboxylic acid (3-oxo-propyl)-amide 1b were synthesized according to our previous methods described in literature [19].

3-(4-Oxo-2-thioxo-thiazolidin-3-yl)-propionic acid (2c)

In a 25 mL two-necked round-bottomed ask provided with a magnetic stirrer and condenser, -alanine (500 mg,5.61 mmol) was solubilized in a solution of 22% potassium hydroxide at room temperature. To this homogeneous solution was added carbon disulde (0.37 mL, 6.12 mmol) drop-wise during 10 min at 25 C. After stirring over a period of 3 h, commercial bromoacetic acid (781 mg, 5.61 mmol)

was added in small portions to the reaction mixture. The yellowish solution was vigorously stirred at 25 C during 3 h. The resulting orange solution was acidied at pH 4 with conc sulfuric acid then, stirred over a period of 16 h and orange needles appeared in the suspension. The insoluble product 2c was collected by ltration and dried under high vacuum (102 Torr) at 25 C for 2 h. The product 2c (503 mg, 44% yield) was further used without purication.

Mp = 162164 C. 1H NMR (DMSO-d6) : 4.05 (m, 4H, H-3, CH2); 4.22 (s, 2H, H-5 , CH2). 13C NMR (DMSO-d6) : 30.57 (C-2, CH2CO); 35.90 (C-3, NCH2); 39.57 (C-5 , CH2S); 171.04 (C-1, C=O); 174.04 (C-4 , C=O); 202.96 (C-2 , C=S). HRMS, m/z: 249.9585 found (calculated for

C6H6NO3Na2S2 [MH+2Na]+ requires 249.9585).

N-(4-Oxo-2-thioxo-thiazolidin-3-yl)-benzenesulfonamide (2e)

In a 25 mL two-necked round-bottomed ask provided with a magnetic stirrer and condenser, a suspension of commercial phenylsulfonyl hydrazine (500 mg, 2.9 mmol) in 3 mL of deionized water was vigorously stirred at 95 C during 2 h and produced an homogeneous yellow solution. To this solution was added commercial bis-(carboxymethyl)trithiocarbonate (657 mg, 2.9 mmol). The reaction mixture was stirred at 95 C over a period of 22 h. Water was evaporated in vacuo during 7 h and the desired insoluble compound 2e was collected by ltration then was submitted to purication by recrystallization in 3 mL of absolute ethanol. The product 2e was obtained as white needles in 41% yield (344 mg). Mp = 152 154 C. 1H NMR (DMSO-d6) : 4.75 (s, 2H, H-5 , CH2);

123

382 Mol Divers (2014) 18:375388

8.03 (m, 2H, H-3, Ar); 8.13 (m, 1H, H-4, Ar); 8.37 (m, 2H, H-3, Ar); 11.31 (br s, 1H, NH). 13C NMR (DMSO-d6) : 32.95 (C-5 , CH2S); 127.23 (C-2, Ar); 128.97 (C-3, Ar); 133.34 (C-4, Ar); 140.78 (C-1, Ar); 170.30 (C-4 , C=O); 199.40 (C-2 , C=S). HRMS, m/z: 310.9594 found (calculated for

C9H8N2O3NaS3 [M+Na]+ requires 310.9594).

N-(4-Oxo-2-thioxo-thiazolidin-3-yl)-benzamide (2f)

In a 25 mL round-bottomed ask provided with a magnetic stirrer and condenser, a mixture of commercial 3-amino rhodanine 2d (500 mg, 3.37 mmol) and benzoyl chloride (0.39 mL, 3.37 mmol) was stirred in 5 mL of dry tetrahydrofuran at 60 C during 2 h. The solvent of the reaction mixture was eliminated in a rotary evaporator under reduced pressure and the yellowish crude residue crystallized after cooling down to room temperature. The crude solid was washed with toluene (25 mL) and was collected by ltration. The desired product

2f was obtained as a yellowish powder in 90% yield (767 mg) and was further used without purication. Mp = 196198 C.

1H NMR (DMSO-d6) : 4.53 (s, 2H, H-5 , CH2); 7.56 (m,

2H, H-3, Ar); 7.66 (m, 1H, H-4, Ar); 7.93 (m, 2H, H-2, Ar);

11.56 (br s, 1H, NH). 13C NMR (DMSO-d6) : 33.43 (C-5 , CH2S); 127.75 (C-2, Ar); 128.72 (C-3, Ar); 130.90 (C-1, Ar); 132.76 (C-4, Ar); 164.44 (NHC=O); 170.42 (C-4 , C=O);

200.14 (C-2 , C=S). HRMS, m/z: 274.9927 found (calculated for C10H8N2O2NaS2 [M+Na]+ requires 274.9925).

4-Methoxy-N-(4-oxo-2-thioxo-thiazolidin-3-yl)-benzamide (2g)

In a 25 mL round-bottomed ask provided with a magnetic stirrer and condenser, a mixture of commercial 3-amino rhodanine 2d (300 mg, 2.02 mmol) and pmethoxybenzoyl

chloride (345 mg, 2.02 mmol) was dispersed in 3 mL of dry toluene. The reaction mixture was heated at 50 C under vigorous magnetic stirring and the reaction was monitored by TLC on silica plates using dichloromethane/ethanol (9:1) as eluent (2g R f 0.8). After 8 h, the solvent of the reaction mixture was eliminated in a rotary evaporator under reduced pressure and the crude oil was dried under high vacuum (102 Torr) at 25 C for 3 h. The crude oil crystallized after standing at room temperature. The desired product 2g was obtained as yellowish powder in 98% yield (570 mg) and was further used without purication. Mp = 190 192 C. 1H NMR (DMSO-d6) : 3.84 (s, 3H, CH3O); 4.51 (s, 2H, H-5 , CH2S); 7.08 (d, 2H, J = 8.9 Hz, H-3, Ar); 7.92 (d, 2H, J = 8.9 Hz, H-2, Ar); 11.39 (br s, 1H, NH). 13C

NMR (DMSO-d6) : 33.34 (C-5 , CH2S); 55.48 (CH3O); 113.95 (C-3, Ar); 122.96 (C-1, Ar); 129.79 (C-2, Ar); 162.67 (C-4, Ar); 163.79 (NHC=O); 170.51 (C-4 , C=O); 200.29 (C-2 , C=S). HRMS, m/z: 305.0031 found (calculated for

C11H10N2O3NaS2 [M+Na]+ requires 305.0030).

N-(4-Oxo-2-thioxo-thiazolidin-3-yl)-2-phenyl-acetamide (2h)

In a 25 mL round-bottomed ask provided with a magnetic stirrer and condenser, a mixture of commercial 3-amino rhodanine 2d (300 mg, 2.02 mmol) and phenylacetyl chloride(0.27 mL, 2.02 mmol) was dispersed in 3 mL of dry toluene. The reaction mixture was heated at 50 C under vigorous magnetic stirring and the reaction was monitored by TLC on silica plates using dichloromethane/ethanol (9:1) as eluent (2h R f 0.75). After 8 h, the solvent of the reaction mixture was eliminated in a rotary evaporator under reduced pressure and the crude product was dried under high vacuum (102 Torr) at 25 C for 3 h. The desired product 2h was obtained as yellowish powder in 98% yield (538 mg) and was further used without purication. Mp = 172174 C.

1H NMR (DMSO-d6) : 3.66 (s, 2H, CH2); 4.404.41 (br s, 2H, H-5 , CH2S); 7.317.32 (m, 5H, H-2, H-3, H-4, Ar);

11.41 (br s, 1H, NH). 13C NMR (DMSO-d6) : 33.38 (C-5 , CH2S); 126.52 (C-4, Ar); 128.19 (C-3, Ar); 129.11 (C-2,

Ar); 134.65 (C-1, Ar); 168.39 (NHC=O); 170.18 (C-4 C=O); 199.99 (C-2 , C=S). HRMS, m/z: 289.0082 found (calculated for C11H10N2O2NaS2 [M+Na]+ requires 289.0081).

N-(4-Oxo-2-thioxo-thiazolidin-3-yl)-3-phenylpropionamide (2i)

In a 25 mL round-bottomed ask provided with a magnetic stirrer and condenser, a mixture of commercial 3-amino rhodanine 2d (50 mg, 0.34 mmol) and 2-phenylpropionyl chlo-ride (50 L, 0.34 mmol) was dispersed in 1 mL of dry toluene. The reaction mixture was heated at 50 C under vigorous magnetic stirring and the reaction was monitored by TLC on silica plates using dichloromethane/ethanol (9:1) as eluent (2i R f 0.75). After 23 h, the solvent of the reaction mixture was eliminated in a rotary evaporator under reduced pressure. The crude residue was dissolved in dichloromethane (15 mL) then, this organic layer was washed with 4 mL of saturated hydrogen carbonate NaHCO3 and was dried over

MgSO4. After ltration, the solvent of the ltrate was eliminated in vacuo and the crude residue was dried under high vacuum (102 Torr) at 25 C for 1 h. The desired product 2i was obtained as orange powder in 84% yield (80 mg)

and was further used without purication. Mp = 190192 C . 1H NMR (DMSO-d6) : 2.67 (dd, 2H, J = 6.3, 8.3 Hz,

2H, CH2Ar); 2.95 (m, 2H, CH2CO); 4.474.48 (br s, 1H, H-5 , CH2S); 7.327.35 (m, 5H, H-2, H-3, H-4, Ar); 11.05 (br s, 1H, NH). 13C NMR (DMSO-d6) : 30.41 (CH2Ar);33.32 (CH2CO); 34.49 (C-5 , CH2S); 126.02128.27 (C-2, C-3, C-4, Ar); 140.53 (C-1, Ar); 169.79 (NHC=O); 170.24 (C-4 , C=O); 200.03 (C-2 , C=S). HRMS, m/z: 303.0239 found (calculated for C12H12N2O2NaS2 [M+Na]+ requires 303.0238).

123

Mol Divers (2014) 18:375388 383

Standard procedure for the preparation of 4,5-dihalogeno-1H-pyrrol-2-carboxylic acid [3-(4-oxo-2-thioxothiazolidin-5-ylidene) -propyl]-amide 3(a, b)

In a 10 mL glass tube were placed successively 4,5-dihalogeno-1H-pyrrole-2-carboxylic acid (3-oxo-propyl)-amide 1(a, b) (3.09 mmol), commercial rhodanine 2a (3.09 mmol, 1 equiv.), piperidine (0.31 mmol, 0.1 equiv.) and glacial acetic acid (0.31 mmol, 0.1 equiv.) in 12 mL of absolute ethanol. The glass tube was sealed with a snap cap and placed in the Explorer24 CEM microwave cavity (P = 300 W). The mixture was irradiated at 150 C (with a power of 200 W) for 20 min under vigorous magnetic stirring. After microwave dielectric heating, the crude reaction mixture was allowed to cool down at room temperature and the volatile compounds of the reaction mixture were eliminated in a rotary evaporator under reduced pressure. The crude residue was submitted to purication by preparative chromatography (Combi Flash R f 200 psi apparatus, detector UV 254 nm) on pre-packed column of silica gel 60F 254 Merck using dichloromethane/ethanol (9:1) as eluent.Pooling and evaporation of the solvents in vacuo gave the expected compounds 3(a, b) which, were dried under high vacuum (102 Torr) at 25 C for 1 h.

4,5-Dibromo-1H-pyrrol-2-carboxylic acid [3-(4-oxo-2-thioxo-thiazolidin-5-ylidene)-propyl]-amide (3a)

Orange powder. R f = 0.83. Yield = 88%. Mp = 156 C (decomposition). 1H NMR (DMSO-d6) : 2.41 (m, 2H, CH2CH=); 3.41 (m, 2H, NHCH2); 6.81 (t, 1H, J = 7.6 Hz,

=CH); 6.87 (d, 1H, J = 2.3 Hz, H-3, =CH, Ar); 8.31 (t, 1H,

J = 6.0 Hz, NHCO); 12.71 (br s, 1H, H-1, NH, Ar); 13.60 (br

s, 1H, H-3 , NH). 13C NMR (DMSO-d6) : 32.27 (CH2CH=);36.79 (NHCH2); 97.79 (C-4, =CBr, Ar); 104.69 (C-4 , C=O); 112.59 (C-3, =CH, Ar); 124.74 (C-5 , C=CH); 127.88 (C-5, =CBr, Ar); 130.36 (C-2, Ar); 135.02 (=CH); 159.00 (NH

C=O); 167.49 (C-4 , C=O); 195.95 (C-2 , C=S). HRMS, m/z: 459.8403 found (calculated for C11H9N3O792Br2NaS2 [M+Na]+ requires 459.8401).

4,5-Dichloro-1H-pyrrol-2-carboxylic acid [3-(4-oxo-2-thioxo-thiazolidin-5-ylidene)-propyl]-amide (3b)

Orange powder. R f = 0.79. Yield = 82%. Mp = 180 C (decomposition). 1H NMR (DMSO-d6) : 2.40 (q, 2H, J =

6.5 Hz, CH2CH=); 3.43 (q, 2H, J = 6.5 Hz, NHCH2); 6.82

(m, 1H, =CH); 6.84 (s, 1H, H-3, =CH, Ar); 8.34 (t, 1H, J =

5.8 Hz, NHCO); 12.74 (br s, 1H, NH, Ar); 13.58 (br s, 1H, H-3 , NH). 13C NMR (DMSO-d6) : 32.26 (CH2CH=); 36.80 (NHCH2); 107.92 (C-4, =CCl, Ar); 109.65 (C-3, =CH, Ar); 114.94 (C-4 , C=O); 124.61 (C-5, =CCl, Ar); 124.74 (C-5 , C=CH; 130.38 (C-2, Ar); 134.96 (=CH); 159.12 (NH-

C=O); 167.48 (C-4 , C=O); 195.94 (C-2 , C=S). HRMS, m/z: 371.9411 found (calculated for C11H9N3O352Cl2NaS2 [M+Na]+ requires 371.9411).

(5-{3-[(4,5-Dibromo-1H-pyrrol-2-carbonyl)-amino]-propylidene} -4-oxo-2-thioxothiazolidin-3-yl)-acetic acid (3c)

In a 10 mL glass tube were placed successively 4,5-dibromo-1H-pyrrole-2-carboxylic acid (3-oxo-propyl)-amide 1a (200 mg, 0.62 mmol), commercial 2-(4-oxo-2-thioxo-thiazolidin-3-yl)-acetic acid 2b (118 mg, 0.62 mmol, 1 equiv.), piperi-dine (6 L, 0.062 mmol, 0.1 equiv.), glacial acetic acid (4 L, 0.062 mmol, 0.1 equiv.) in 2.5 mL of absolute ethanol. The glass tube was sealed with a snap cap and placed in the Monowave200 Anton-Paar microwave cavity (P = 800 W). The mixture was irradiated at 110 C for 40 min under vigorous magnetic stirring. After microwave dielectric heating, the crude reaction mixture was allowed to cool down at room temperature and the volatile compounds of the reaction mixture were eliminated in a rotary evaporator under reduced pressure. The crude residue was submitted to purication by preparative chromatography (Combi Flash R f 200 psi apparatus, detector UV 254 nm) on pre-packed column of silica gel 60F 254 Merck using dichloromethane/methanol (9:1) as eluent (3c: R f 0.10). Pooling and evaporation of the solvents in vacuo gave the desired compound 3c which, was dried under high vacuum (102 Torr) at 25 C for 1 h.

3c was obtained as yellow powder in 46% yield (140 mg). Mp = 210212 C. 1H NMR (DMSO-d6) : 2.50 (m, 2H,

CH2CH=); 3.42 (m, 2H, NHCH2); 4.63 (s, 2H, CH2CO);6.87 (s, 1H, =C-H, Ar); 7.07 (t, 1H, J = 7.5 Hz, =CH); 8.35

(t, 1H, J = 5.5 Hz, NHCO); 12.71 (br s, 1H, NH). 13C NMR

(DMSO-d6) : 30.64 (CH2CH=); 36.79 (NHCH2); 44.81 (CH2CO); 97.77 (C-4, =CBr, Ar); 104.48 (C-5 , C=CH);

112.49 (C-3, =CH, Ar); 126.72 (C-5, =CBr, Ar); 127.88 (C-

2, Ar); 137.84 (C=CH); 159.05 (NH-C=O); 164.55 (C-4 ,

C=O); 167.10 (C=O, CO2H); 193.66 (C-2 , C=S). HRMS, m/z: 517.8448 found (calculated for C13H11N3O794Br2NaS2 [M+Na]+ requires 517.8455).

(5-{3-[(4,5-Dibromo-1H-pyrrol-2-carbonyl)-amino]-propylidene} -4-oxo-2-thioxothiazolidin-3-yl)-propionic acid (3d)

In a 10 mL glass tube were placed successively 4,5-dibromo-1H-pyrrole-2-carboxylic acid (3-oxo-propyl)-amide 1a (79 mg, 0.24 mmol), 3-(4-oxo-2-thioxo-thiazolidin-3-yl)-propionic acid 2c (50 mg, 0.24 mmol, 1 equiv.), commercial sodium acetate AcONa (20 mg, 0.24 mmol, 1 equiv.), and glacial acetic acid (90 L, 1.6 mmol, 6.58 equiv.). The glass tube was sealed with a snap cap and placed in the Explorer24 CEM microwave cavity (P = 300 W). The mixture

123

384 Mol Divers (2014) 18:375388

was irradiated at 140 C (with a power of 60 W) for 20 min under vigorous magnetic stirring. After microwave dielectric heating, the crude reaction mixture was allowed to cool down at room temperature and to the oily crude reaction mixture was added 1 mL of deionized water. After triturating, the insoluble product 3d was collected by ltration and was submitted to purication by preparative chromatography (Combi Flash R f 200 psi apparatus, detector UV 254 nm)

on pre-packed column of silica gel 60F 254 Merck using dichloromethane/ethanol (9:1) as eluent (3d R f 0.49). Pooling and evaporation of the solvents in vacuo gave the desired compound 3d which, was dried under high vacuum (102

Torr) at 25 C for 1 h. 3d was obtained as yellowish needles in 46% yield (58 mg). Mp = 90 C (decomposition).

1H NMR (DMSO-d6) : 2.45 (m, 2H, CH2CH=); 2.56 (m,

2H, CH2CO); 3.41 (m, 2H, NHCH2); 4.15 (t, 2H, J = 7.8

Hz, 2H, NCH2); 6.89 (s, 1H, H-3, =C-H, Ar); 7.01 (t, 1H, J = 7.5 Hz, C=CH); 8.32 (t, 1H, J = 5.5 Hz, 1H, NHCO);

12.72 (br s, 1H, H-1, NH, Ar). 13C NMR (DMSO-d6) :30.70 (CH2CH=); 32.23 (CH2CO); 36.82 (NCH2); 97.80 (C-4, =CBr, Ar); 104.72 (C-5, =CBr, Ar); 112.60 (C-3, =CH, Ar); 127.17 (C-5 , C=CH); 127.87 (C-2, Ar); 136.61 (CH=);

159.04 (NH-C=O); 164.86 (C-4 , C=O); 171.67 (CO2H); 193.65 (C-2 , C=S). HRMS, m/z: 507.8636 found (calculated for C14H12N3O794Br2S2 [M-H] requires 507.8636).

4,5-Dibromo-1H-pyrrol-2-carboxylic acid [3-(3-amino-4-oxo- 2-thioxo-thiazolidin-5-ylidene)-propyl]-amide (3e)

In a 10 mL glass tube were placed successively 4,5-dibromo-1H-pyrrole-2-carboxylic acid (3-oxo-propyl)-amide 1a (100 mg, 0.31 mmol), commercial 3-amino rhodanine 2d (46 mg, 0.31 mmol, 1 equiv.), dry triethylamine Et3N (4 L,0.031 mmol, 0.1 equiv.), glacial acetic acid AcOH (2 L,0.031 mmol, 0.1 equiv.) in 1 mL of ethyl acetate AcOEt.

The glass tube was placed (open vessel) in the Explorer24 CEM microwave cavity (P = 300 W) and the mixture was irradiated at 70 C (with a power of 50 W) for 30 min under vigorous magnetic stirring. After microwave dielectric heating, the crude reaction mixture was allowed to cool down at room temperature and to the crude reaction mixture was added 5 mL of cyclohexane. This heterogeneous mixture in the tube was submitted to ultrasound in a Bran-son 1510 apparatus at 25 C during 30 min. The yellowish desired compound 3e was collected by ltration, washed with Et2O (2 5 mL) and was puried by preparative chro

matography (Combi Flash R f 200 psi apparatus, detector UV 254 nm) on pre-packed column of silica gel 60F 254 Merck using dichloromethane/methanol (9:1) as eluent (3e R f 0.69). Pooling and evaporation of the solvents in vacuo gave the desired compound 3e which, was dried under high vacuum (102 Torr) at 25 C for 1 h. 3e was obtained as a yellowish powder in 71% yield (100 mg). 1H NMR

(DMSO-d6) : 2.45 (m, 2H, CH2CH=); 3.41 (m, 2H, NCH2);5.99 (m, 1H, C=CH); 6.95 (s, 1H, H-3, Ar); 8.28 (m, 1H, NH-CO); 12.79 (br s, 1H, NH, Ar). HRMS, m/z: 452.8693 found (calculated for C11H11N4O792Br2S2 [M+H]+ requires 452.8690).

4,5-Dibromo-1H-pyrrol-2-carboxylic acid [3-(3-benz-enesulfonylamino-4-oxo-2-thioxo-thiazolidin-5-ylidene)-propyl]-amide (3f)

In a 10 mL glass tube were placed successively 4,5-dibromo-1H-pyrrole-2-carboxylic acid (3-oxo-propyl)-amide 1a (100 mg, 0.31 mmol), N-(4-oxo-2-thioxo-thiazolidin-3-yl)-benzenesulfonamide 2e (89 mg, 0.31 mmol, 1 equiv.), piperi-dine (3 L, 0.031 mmol, 0.1 equiv.), glacial acetic acid (2 L, 0.031 mmol, 0.1 equiv.) in 1.2 mL of absolute ethanol. The glass tube was sealed with a snap cap and placed in the Monowave200 Anton-Paar microwave cavity (P = 800 W). The mixture was irradiated at 150 C for 20 min under vigorous magnetic stirring. After microwave dielectric heating, the crude reaction mixture was allowed to cool down at room temperature and the volatile compounds of the reaction mixture were eliminated in a rotary evaporator under reduced pressure. To the black crude residue was added Et20 (5 mL)

and after triturating, the insoluble compound 3f was collected by ltration. Then, 3f was submitted to purication by preparative chromatography (Combi Flash R f 200 psi apparatus, detector UV 254 nm) on pre-packed column of silica gel 60F 254 Merck using dichloromethane/methanol (9:1) as eluent (3f R f 0.69). Pooling and evaporation of the solvents in vacuo gave the desired compound 3f which, was dried under high vacuum (102 Torr) at 25 C for 1 h. 3f was obtained as an orange powder in 19% yield (35 mg). Mp = 2424226 C.

1H NMR (DMSO-d6) : 2.45 (m, 2H, CH2CH=); 3.42 (m,

2H, NCH2); 6.87 (d, 1H, J = 2.7 Hz, =CH, Ar); 7.07 (t,

1H, J = 7.6 Hz, =CH); 7.56 (m, 2H, H-3 , Ar); 7.67 (m,

1H, H-4 , Ar); 7.80 (m, 2H, H-2 , Ar); 8.34 (t, 1H, J =

5.9 Hz, NHCO); 11.51 (br s, 1H, NHSO2); 12.71 (br s, 1H, NHPyr). 13C NMR (DMSO-d6) : 31.77 (CH2CH=); 36.66 (NCH2); 97.79 (C-4, =CBr, Ar); 104.74 (C-5, =CBr, Ar); 11260 (C-3, =CH, Ar); 123.41 (C-5 , C=CH); 127.22 (C-2 ,

Ar); 127.87 (C-2, =C-H, Ar); 129.07 (C-3 , Ar); 133.48 (C-4 , Ar); 138.92 (C=CH); 140.59 (C-1 , Ar); 159.05 (NH

C=O); 161.73 (C-4 , C=O); 190.37 (C-2 , C=S). HRMS, m/z: 614.8438 found (calculated for C17H14N4O794Br2NaS2 [M+Na]+ requires 614.8442).

Standard procedure for the preparation of 4,5-dibromo-1H-pyrrol-2-carboxylic acid [3-(3-substituted amino-4-oxo-2-thioxo-thiazolidin-5-ylidene)-propyl]-amide (3g) and 3(i, j).

In a 10 mL glass tube were placed successively 4,5-dibromo-1H-pyrrole-2-carboxylic acid (3-oxo-propyl)-amide 1a (52

123

Mol Divers (2014) 18:375388 385

122 mg, 0.160.38 mmol), N-acyl rhodanine 2(fi) (45100 mg, 0.160.38 mmol, 1 equiv.), commercial sodium acetate AcONa (1431 mg, 0.160.38 mmol, 1 equiv.), and glacial acetic acid (61140 L, 1.062.47 mmol, 6.58 equiv.). The glass tube was sealed with a snap-cap and placed in the Explorer24 CEM microwave cavity (P = 300 W). The mixture was irradiated at 120 C (with a power of 100 W) for 20 min under vigorous magnetic stirring. After microwave dielectric heating, the crude reaction mixture was allowed to cool down at room temperature and deionized water (2 mL) was added to the brown crude reaction mixture. The resulting suspension was submitted to ultrasound in a Bran-son 1510 apparatus at 25 C during 30 min and the beige insoluble product 3 was collected by ltration. Then, compound 3 was triturated in 5 mL of Et2O for compounds 3g and 3(i, j) or in 5 mL of dichloromethane for compound 3h* and again was collected by ltration. The crude products 3g and 3(i, j) were puried by preparative chromatography (Combi Flash R f 200 psi apparatus, detector UV 254 nm) on pre-packed column of silica gel 60F 254 Merck using dichloromethane/methanol (9:1) as eluent. Pooling and evaporation of the solvents it in vacuo gave the expected compound 3g and 3(i, j) and were dried under high vacuum (102 Torr) at 25 C during 1 h. (*) The compound 3h was puried by recrystallization in dichloromethane

CH2Cl2.

4,5-Dibromo-1H-pyrrol-2-carboxylic acid [3-(3-benz-oylamino-4-oxo-2-thioxo-thiazolidin-5-ylidene)-propyl]-amide (3g)

Compound 3g (R f 0.69) was prepared in 52% yield (90 mg) from 4,5-dibromo-1H-pyrrole-2-carboxylic acid (3-oxo-propyl)-amide 1a (100 mg, 0.31 mmol), N-(4-oxo-2-thioxo-thiazolidin-3-yl)-benzamide 2f (78 mg, 0.31 mmol), sodium acetate AcONa (25 mg, 0.31 mmol) in glacial acetic acid (120 L, 2 mmol, 6.58 equiv.) according to the standard procedure. Mp = 242244 C. 1H NMR (DMSO-d6) :2.50 (m, 2H, CH2CH=); 3.33 (m, 2H, NCH2); 6.89 (d, 1H, J = 2.7 Hz, =CH, Ar); 7.20 (t, 1H, J = 7.6Hz, =CH);

7.57 (m, 2H, H-3 , Ar); 7.67 (m, 1H, H-4 , Ar); 7.94 (m, 2H, H-2 , Ar); 8.39 (t, 1H, J = 6.1 Hz, NHCO); 11.72

(br s, 1H, NNHCO); 12.74 (br s, 1H, NH, Ar). 13C NMR (DMSO-d6) : 31.98 (CH2CH=); 36.75 (NCH2); 97.80 (C-4, =CBr, Ar); 104.76 (C-5, =CBr, Ar); 112.61 (C-3, =CH, Ar); 123.84 (C-5 , =C); 127.73 (C-2 , Ar); 127.88 (C-2, =C-CO, Ar); 128.79 (C-3 , Ar); 130.66 (C-1 , Ar); 132.89 (=C); 139.36 (C-4 , Ar); 159.08 (NH-C=O); 161.70 (C-4 , C=O); 164.43 (NNHC=O); 191.14 (C-2 , C=S). HRMS, m/z: 578.8774 found (calculated for C18H14N4O794Br2NaS2 [M+Na]+ requires 578.8772).

4,5-Dibromo-1H-pyrrol-2-carboxylic acid {3-[3-(4-methoxy-benzoylamino)-4-oxo-2-thioxo-thiazolidin-5-ylidene]-propyl}-amide (3h)

Compound 3h was prepared in 74% yield (154 mg) from 4,5-dibromo-1H-pyrrole-2-carboxylic acid (3-oxo-propyl)-amide 1a (115 mg, 0.35 mmol), 4-methoxy-N-(4-oxo-2-thioxo-thiazolidin-3-yl)-benzamide 2g (100 mg, 0.35 mmol), sodium acetate AcONa (29 mg, 0.35 mmol) in glacial acetic acid (130 L, 2.33 mmol, 6.58 equiv.) according to the standard procedure. Mp = 190 C(decomposition).

1H NMR (DMSO-d6) : 2.53 (m, 2H, CH2CH=); 3.45 (m, 2H, NCH2); 3.84 (s, 3H, CH3O); 6.89 (d, 1H, J =

2.6 HZ, H-3, =CH, Ar); 7.09 (m, 2H, H-3 , Ar); 7.18 (t, 1H, J = 7.7 Hz, C=CH); 7.91 (m, 2H, H-2 , Ar);

8.38 (t, 1H, J = 5.5 Hz, 1H, NHCO); 11.53 (s, 1H,

NNHCO); 12.73 (br s, 1H, NH, Ar). 13C NMR (DMSO-

d6): 31.95 (CH2CH=); 36.74 (NCH2); 55.49 (CH3O);97.81 (C-4, =CBr, Ar); 104.76 (C-5, =CBr, Ar); 112.60 (C-3, =CH, Ar); 114.03 (C-3 , Ar); 114.82 (C-3 , Ar);

122.70 (C-5 , =C); 123.90 (C-2, =C-CO, Ar); 127.81 (C-

2 , Ar); 129.80 (C-2 , Ar); 139.21 (CH=); 159.09 (C-1 ,

Ar); 160.55 (C-4 , Ar); 162.77 (NH-C=O); 163.84 (C-4 , C=O); 166.31 (NNHC=O); 196.11 (C-2 , C=S). HRMS, m/z: 608.8875 found (calculated for C20H20N4O795Br2NaS2 [M+Na]+ requires 608.8874).

4,5-Dibromo-1H-pyrrol-2-carboxylic acid [3-(4-oxo-3-phenylacetylamino-2-thioxo-thiazolidin-5-ylidene)-propyl]-amide (3i)

Compound 3i (R f 0.71) was prepared in 58% yield (126 mg) from 4,5-dibromo-1H-pyrrole-2-carboxylic acid (3-oxo-propyl)-amide 1a (122 mg, 0.38 mmol), N-(4-oxo-2-thioxo-thiazolidin-3-yl)-2-phenyl-acetamide 2h (100 mg,0.38 mmol), sodium acetate AcONa (31 mg, 0.38 mmol) in glacial acetic acid (140 L, 2.47 mmol, 6.58 equiv.) according to the standard procedure. Mp = 100 C (decomposition). 1H NMR (DMSO-d6) : 2.53 (m, 2H, CH2CH=);3.43 (m, 2H, NCH2); 3.66 (s, 2H, CH2CONH); 6.87 (d, 1H, J = 2.7 Hz, =CH, Ar); 7.12 (t, 1H, J = 7.6 Hz,

C=CH); 7.297.33 (m, 5H, H-2 , H-3 , H-4 , Ar); 8.36 (t, 1H, J = 5.9 Hz, NHCO); 11.36 (s, 1H, NNHCO);

12.71 (br s, 1H, NH, Ar). 13C NMR (DMSO-d6) : 28.98 (CH2CH=); 31.89 (NHCOCH2); 36.74 (NCH2); 97.81 (C-4, =CBr, Ar); 104.74 (C-5 , C=CH); 122.62 (C-3, =CH,

Ar); 123.98 (C-5, =CBr, Ar); 126.72 (C-4 , Ar); 127.87 (=C-CO, Ar); 128.26 (C-3 , Ar); 129.11 (C-2 , Ar); 134.53 (C-1 , Ar); 138.81 (C=CH); 159.08 (NH-C=O); 161.53 (C-4 , C=O); 168.53 (NNHC=O); 190.99 (C-2 , C=S). HRMS, m/z: 592.8927 found (calculated for C19H16N4O793Br2NaS2 [M+Na]+ requires 592.8928).

123

386 Mol Divers (2014) 18:375388

4,5-Dibromo-1H-pyrrol-2-carboxylic acid {3-[4-oxo-3-(3-phenyl-propionylamino)-2-thioxo-thiazolidin-5-ylidene]-propyl}-amide (3j)

Compound 3j (R f 0.77) was prepared in 49% yield (46 mg) from 4,5-dibromo-1H-pyrrole-2-carboxylic acid (3-oxo-propyl)-amide 1a (52 mg, 0.16 mmol), N-(4-oxo-2-thioxo-thiazolidin-3-yl)-3-phenyl-propionamide 2i (45 mg,0.16 mmol), sodium acetate AcONa (14 mg, 0.16 mmol) in glacial acetic acid (61 L, 1.06 mmol, 6.58 equiv.) according to the standard procedure. Mp = 100 C (decomposition). 1H NMR (DMSO-d6) : 2.62 (m, 2H, CH2CO); 2.88 (m, 2H, CH2Ar); 3.43 (m, 2H, NCH2); 6.88 (d, 1H, J =

2.5 Hz, =CH, Ar); 7.13 (t, 1H, J = 7.6 Hz, C=CH); 7.23-

7.31 (m, 5H, H-2 , H-3 , H-4 , Ar); 8.36 (t, 1H, J = 5.9

Hz, NHCO); 11.15 (s, 1H, NNHCO); 12.72 (br s, 1H, H-1, NH, Ar). 13C NMR (DMSO-d6) : 30.36 (CH2CH=);

31.87 (CH2Ar); 34.45 (CH2CO); 36.75 (NHCH2); 97.79 (C-4, =CBr, Ar); 104.74 (C-5, =CBr, Ar); 112.60 (C-3, =CH, Ar); 123.99 (C-5 , C=CH); 126.04 (C-4 , Ar); 127.87 (C-2, =CCO, Ar); 128.23 (C-2 , Ar); 128.28 (C-3 , Ar); 138.73 (=CH); 140.45 (C-1 , Ar); 159.07 (NH-C=O); 161.58 (C-4 , C=O); 169.91 (NNHC=O); 191.02 (C-2 , C=S). HRMS, m/z: 606.9084 found (calculated for C20H18N4O793Br2NaS2 [M+Na]+ requires 606.9085).

X-ray crystallographic data for 4,5-dibromo-1H-pyrrol-2-carboxylic acid [3-(4-oxo-2-thioxothiazolidin-5-ylidene)-propyl]-amide (3a)

(2(C11 H9 Br2 N3 O2 S2)); M = 878.3. APEXII, Bruker-AXS diffractometer, Mo-K radiation ( = 0.71073 ), T = 150(2) K; triclinic P-1 (I.T.#2), a = 7.0648(6), b =

14.9877(13), c = 17.6708(13), = 75.216(3), =

87.475(3), = 78.233(3), V = 1771.1(3) 3, Z = 2, d =1.647 gcm3, = 4.815 mm1. The structure was solved by direct methods using the SIR97 program [46], and then rened with full-matrix least-square methods based on F2 (SHELXL-97) [47] with the aid of the WINGX [48]program.The contribution of the disordered solvents to the calculated structure factors was estimated following the BYPASS algorithm [49], implemented as the SQUEEZE option in PLATON [50]. A new data set, free of solvent contribution, was then used in the nal renement. All non-hydrogen atoms were rened with anisotropic atomic displacement parameters. H atoms were nally included in their calculated positions. A nal renement on F2 with 8064 unique intensities and 361 parameters converged at R(F2) = 0.2134(R(F) = 0.0795)

for 2888 observed reections with I > 2(I). Crystallo-graphic data for the structure of 3a in this paper have been deposited in the Cambridge Crystallographic Data Centre as supplementary publication number CCDC 938832. Copies of the data can be obtained, free of charge, on application

to CCDC, 12 Union Road, Cambridge CB21EZ, UK [fax: [phone] or e-mail:[email protected]].

Biochemistry part

Protein kinase assay buffers

Buffer A 10 mM MgCl2, 1 mM EGTA, 1 mM DTT, 25 mM TrisHCl pH 7.5, 50 g heparin/mL. Buffer B 50 mM MgCl2, 90 mM NaCl, 30 mM TrisHCl pH 7.4.

Kinase preparations and assays

Kinase activities for each enzyme were assayed in buffer A or B, with their corresponding substrates, in the presence of 15 M ATP in a nal volume of 30 L. After 30-min incubation at 30 C, the reaction was stopped by harvesting, using a FilterMate harvester (Packard), onto P81 phosphocellulose papers (GE Healthcare) which were washed in 1% phosphoric acid. Scintillation uid was added and the radioactivity measured in a Packard counter. Blank values were subtracted and activities calculated as pmoles of phosphate incorporated during the 30-min incubation. The activities were expressed in % of the maximal activity, i.e., in the absence of inhibitors. Controls were performed with appropriate dilutions of DMSO.

CDK1/cyclin B (M phase starsh oocytes, native), CDK2/ cyclin E (human, recombinant, from A. Echalier), and CDK5/p25 (human, recombinant, expressed in E. coli) [51] were assayed in Buffer A (supplemented extemporaneously with 0.15 mg BSA/mL, except for CDK2) with 25 g of histone H1.

DYRK1A (rat, recombinant, expressed in E. coli as GST fusion protein, provided by Dr. W. Becker), DYRK1A (human, recombinant, expressed in E. coli as GST fusion proteins), DYRK4 (human, recombinant, expressed in insect cells), CLK1, 2, 3, and 4 (mouse, recombinant, expressed inE. coli as GST fusion proteins) was assayed as described for CDK1/cyclin B with 1 g of RS peptide (GRSRSRSRSRSR) as a substrate. Native DYRK1A was puried from rat brain, taking advantage of the natural poly-histidine sequence located in the C-terminal domain of DYRK1A, by afnity chromatography on cobaltsepharose beads (Clontech). Briey, after a 30-min preclearing incubation at 4 C with sepharose beads, rat brain lysates were incubated with cobalt-sepharose beads (400 g total proteins/20 L beads). Kinase activity of native DYRK1A was directly assessed on the beads in buffer A (+0.5 mg BSA/mL) using the Woodtide substrate (KKISGRLSPIMTEQ).

GSK-3/ (porcine brain, native, afnity puried on axinsepharose beads), GSK-3 and GSK3 (human, recombinant, expressed in insect cells) and PfGSK-3 (Plasmodium falciparum, recombinant, expressed in E. coli) were assayed

123

Mol Divers (2014) 18:375388 387

as described for CDK1/cyclin B, but using a GSK-3 specic substrate (GS-1: YRRAAVPPSPSLSRHSSPHQpSEDEEE, where pS stands for phosphorylated serine) [52].

Casein kinase 1 (CK1/) (porcine brain, native) was assayed with 0.67 g of CKS peptide (RRKHAAIGp-SAYSITA), a CK1 specic substrate [53].

CLK1 (mouse, recombinant, expressed in E. coli as GST fusion proteins) was assayed in buffer A (+0.15 mg BSA/mL) with RS peptide (GRSRSRSRSRSR) (1 g/assay).

Acknowledgments One of us (S.G.) wishes to thank the Ministre de la Recherche et de lEnseignement Suprieur for research fellowships.Financial support of this program carried out under the French National Cancer Institute Cancrople Grand Ouest by contracts PRIR 04-8390 and ACI 04-2254, is gratefully acknowledged.

References

1. Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, Toyota T, Nakashima M, Yoshimura I, Sakamoto N, Shigeta Y (2006) Long-term clinical effects of Epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy. Diabetes Care 29:15381544. doi:http://dx.doi.org/10.2337/dc05-2370

Web End =10.2337/dc05-2370

2. El-Kabbani Ruiz F, Darmanim C, Chung RP-T (2004) Aldose reductase structures: implications for mechanism and inhibition. Cell Mol Life Sci 61:750752. doi:http://dx.doi.org/10.1007/s00018-003-3403-2

Web End =10.1007/s00018-003-3403-2

3. Heng S, Tieu W, Hautmann S, Kuan K, Pedersen DS, Pietsch M, Gutschow M, Abell AD (2011) New cholesterol esterase inhibitors based on rhodanine and thiazolidinedione scaffolds. Bioorg Med Chem 19:74537463. doi:http://dx.doi.org/10.1016/j.bmc.2011.10.042

Web End =10.1016/j.bmc.2011.10.042

4. Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T, Yuan J (2001) Identication of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat

Cell Biol 3:173182. doi:http://dx.doi.org/10.1038/35055085

Web End =10.1038/35055085 5. Wang L, Kong F, Kokoski CL, Andrews DW, Xing C (2008) Development of dimeric modulators for anti-apoptotic Bcl-2 proteins. Bioorg Med Chem Lett 18:236240. doi:http://dx.doi.org/10.1016/j.bmcl.2007.10.088

Web End =10.1016/j.bmcl.2007.10. http://dx.doi.org/10.1016/j.bmcl.2007.10.088

Web End =088

6. Summerer D, Rudinger N-Z, Ilka Detmer I, Marx A (2005) Enhanced delity in mismatch extension by DNA polymerase through directed combinatorial enzyme design. Angew Chem Int Ed 44:47124715. doi:http://dx.doi.org/10.1002/anie.200500047

Web End =10.1002/anie.200500047

7. Strittmatter T, Bareth B, Immel TA, Huhn T, Mayer TU, Marx A (2011) Small molecule inhibitors of human DNA polymerase . Chem Biol 6:314319. doi:http://dx.doi.org/10.1021/cb100382m

Web End =10.1021/cb100382m

8. Bulic B, Pickhardt M, Schmidt B, Mandelkow EM, Waldmann H, Mandelkow E (2009) Development of tau aggregation inhibitors for Alzheimers disease. Angew Chem Int Ed 48:17401752. doi:http://dx.doi.org/10.1002/anie.200802621

Web End =10. http://dx.doi.org/10.1002/anie.200802621

Web End =1002/anie.200802621

9. Bulic B, Pickhardt M, Mandelkow EM, Mandelkow E (2010) Tau protein and tau aggregation inhibitors. Neuropharmacology 59:276289. doi:http://dx.doi.org/10.1016/j.neuropharm.2010.01.016

Web End =10.1016/j.neuropharm.2010.01.016

10. Mishra R, Bulic B, Sellin D, Jha S, Waldmann H, Winter R (2008) Small-molecule inhibitors of islet amyloid polypeptide bril formation. Angew Chem Int Ed 47:46794682. doi:http://dx.doi.org/10.1002/anie.200705372

Web End =10.1002/anie. http://dx.doi.org/10.1002/anie.200705372

Web End =200705372

11. Whitesitt C-A, Simon R-L, Reel J-K, Sigmund S-K, Phillips M-L, Shadle J-K, Heinz L-J, Koppel G-A, Hunden D-C, Lifer S-L, Berry D, Ray J, Little S-P, Liu X, Marshall W-S, Panetta J-A (1996) Synthesis and structureactivity relationships of benzophenones as inhibitors of cathepsin D. Bioorg Med Chem Lett 6:21572162. doi:http://dx.doi.org/10.1016/0960-0894X(96)00393-9

Web End =10.1016/0960-0894X(96)00393-9

12. Kumar G, Parasuraman P, Sharma SK, Banerjee T, Karmodiya K, Surolia N, Surolia A (2007) Discovery of a rhodanine class of compounds as inhibitors of Plasmodium falciparum enoylacyl carrier protein reductase. J Med Chem 50:26652675. doi:http://dx.doi.org/10.1021/jm061257w

Web End =10.1021/ http://dx.doi.org/10.1021/jm061257w

Web End =jm061257w

13. Soltero-Higgin M, Carlson E-E, Phillips J-H, Kiessling L-L (2004) Identication of inhibitors for UDP-galactopyranose mutase. J Am Chem Soc 126:1053210533. doi:http://dx.doi.org/10.1021/ja048017v

Web End =10.1021/ja048017v

14. Powers J-P, Piper D-E, Li Y, Mayorga V, Anzola J, Chen J-M, Jaen J-C, Lee G, Liu J, Peterson M-G, Tonn G-R, Ye Q, Walker NPC, Wang Z (2006) SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase. J Med Chem 49:10341046. doi:http://dx.doi.org/10.1021/jm050859x

Web End =10.1021/jm050859x

15. Rajamaki S, Innitzer A, Falciani C, Tintori C, Christ F, Witvrouw M, Debyser Z, Massa S, Botta M (2009) Exploration of novel thiobarbituric acid-, rhodanine- and thiohydantoin-based HIV-1 integrase inhibitors. Bioorg Med Chem Lett 19:36153618. doi:http://dx.doi.org/10.1016/j.bmcl.2009.04.132

Web End =10. http://dx.doi.org/10.1016/j.bmcl.2009.04.132

Web End =1016/j.bmcl.2009.04.132

16. Dayam R, Sanchez T, Neamati N (2005) -Diketo acid pharmacophore. 1. Discovery of structurally diverse inhibitors of HIV-1 integrase inhibitors. J Med Chem 48:111120. doi:http://dx.doi.org/10.1021/jm0496077

Web End =10.1021/ http://dx.doi.org/10.1021/jm0496077

Web End =jm0496077

17. Kodimuthali A, Jabaris SSL, Pal M (2008) Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. J Med Chem 51:5471 5885. doi:http://dx.doi.org/10.1021/jm800582j

Web End =10.1021/jm800582j

18. Sherida L, Johnson SL, Chen L-H, Harbach R, Sabet M, Savinov A, Cotton NJH, Strongin A, Guiney D, Pellecchia M (2008) Rhodanine derivatives as selective protease inhibitors against bacterial toxins. Chem Biol Drug Des 71:131139. doi:http://dx.doi.org/10.1111/j.1747-0285.2007.00617.x

Web End =10.1111/j. http://dx.doi.org/10.1111/j.1747-0285.2007.00617.x

Web End =1747-0285.2007.00617.x

19. Bazureau J-P, Carreaux F, Renault S, Meijer L, Lozach O, Patent WO 2009/05032 A2, 23 April 2009. Demande PCT/FR 2008/001152, 01 October 2008

20. Debdab M, Renault S, Lozach O, Meijer L, Paquin L, Carreaux F, Bazureau J-P (2010) Synthesis and preliminary biological evaluation of new derivatives of the marine alkaloid leucettamine B as kinase inhibitors. Eur J Med Chem 45:805810. doi:http://dx.doi.org/10.1016/j.ejmech.2009.10.009

Web End =10.1016/j. http://dx.doi.org/10.1016/j.ejmech.2009.10.009

Web End =ejmech.2009.10.009

21. Debdab M, Carreaux F, Renault S, Soundararajan M, Federov O, Lozach O, Babault L, Baratte B, Ogawa Y, Hagiwara M, Einsenreich A, Rauch U, Knapp S, Meijer L, Bazureau J-P (2011) Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specicity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J Med Chem 54:41724186. doi:http://dx.doi.org/10.1021/jm200274d

Web End =10.1021/ http://dx.doi.org/10.1021/jm200274d

Web End =jm200274d

22. Tahtouh T, Federov O, Soundararajan M, Burgy G, Durieu E, Lozach O, Cochet C, Schmid R-S, Lo D-C, Delhommel F, Oberholzer A-E, Pearl L-H, Carreaux F, Bazureau J-P, Knapp S, Meijer L (2012) Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. J Med Chem 55:93129330. doi:http://dx.doi.org/10.1021/jm301034u

Web End =10.1021/jm301034u

23. Burgy G, Tahtouh T, Durieu E, Josselin-Foll B, Limanton E, Meijer L, Carreaux F, Bazureau J-P (2013) Chemical synthesis and biological validation of immobilized protein kinase inhibitory leucettines. Eur J Med Chem 62:728737. doi:http://dx.doi.org/10.1016/j.ejmech.2013.01.035

Web End =10.1016/j.ejmech.2013.01.035

24. Caeri F, Fattorusso E, Mangoni A, Taglialatela-Scafati O (1996) Dispacamides, anti-Histamine alkaloids from Caribbean Agelas Sponges. Tetrahedron Lett 37:35873590. doi:http://dx.doi.org/10.1016/0040-4039(96)00629-6

Web End =10.1016/ http://dx.doi.org/10.1016/0040-4039(96)00629-6

Web End =0040-4039(96)00629-6

25. Guiheneuf S, Paquin L, Carreaux F, Durieu E, Meijer L, Bazureau JP (2012) An efcient approach to dispacamide A and its derivatives. Org Biomol Chem 10:978987. doi:http://dx.doi.org/10.1039/c1ob06161e

Web End =10.1039/c1ob06161e

123

388 Mol Divers (2014) 18:375388

26. Guiheneuf S, Paquin L, Carreaux F, Durieu E, Meijer L, Bazureau J-P (unpublished results)

27. de la Hoz A, Loupy A (eds) (2012) Microwave in organic synthesis.

Wiley-VCH, Weinheim. ISBN 978-3-527-33116-1

28. Bazureau J-P, Draye M (eds) (2011) Ultrasound and microwave: recent advances in organic chemistry. Research Signpost, Kerala.ISBN 978-81-7895-532-2

29. Radi M, Botta M, Falchi F, Maga G, Baldanti F, Paolucci S, Patent WO 2011/039735, 07 April 2011. Demande PCT/IT 2010/054475,04 October 2010

30. Kamila S, Biehl ER (2012) Microwave-assisted synthesis of novel bis(2-thioxothiazolidin-4-one) derivatives as potential GSK-3 inhibitors. Tetrahedron Lett 53:39984003. doi:http://dx.doi.org/10.1016/j.tetlet.2012.05.088

Web End =10.1016/j.tetlet. http://dx.doi.org/10.1016/j.tetlet.2012.05.088

Web End =2012.05.088

31. Nitsche C, Klein CD (2012) Aqueous microwave-assisted one-pot synthesis of N-substituted rhodanines. Tetrahedron Lett 53:5197 5201. doi:http://dx.doi.org/10.1016/j.tetlet.2012.07.002

Web End =10.1016/j.tetlet.2012.07.002

32. Heng S, Tieu W, Hautmann S, Kuan K, Pedersen DS, Pietsch M, Gtschow M, Abell AD (2011) New cholesterol esterase inhibitors based on rhodanine and thiazolidinedione scaffolds. Bioorg Med Chem 19:74537463. doi:http://dx.doi.org/10.1016/j.bmc.2011.10.042

Web End =10.1016/j.bmc.2011.10.042

33. Safonov I-G, Heerding D-A, Keenan R-M, Price A-T, Erickson-Muller C-L, Hopson C-B, Levin J-L, Lord K-A, Tapley P-M (2006)New benzimidazoles as thrombopoietin receptor agonists. Bioorg Med Chem Lett 16:12121216. doi:http://dx.doi.org/10.1016/j.bmcl.2005.11.096

Web End =10.1016/j.bmcl.2005.11.096

34. Tomai T, Zidar N, Rupnik V, Kova A, Blanot D, Gobec S, Kikelj D, Mai LP (2009) Synthesis and biological evaluation of new glutamic acid-based inhibitors of MurD ligase. Bioorg Med Chem Lett 19:153157. doi:http://dx.doi.org/10.1016/j.bmcl.2008.10.129

Web End =10.1016/j.bmcl.2008.10.129

35. Tomai T, Zidar N, Mueller-Premru M, Kikelj D, Mai LP (2010) Synthesis and antibacterial activity of 5-ylidenethiazolidin-4-ones and 5-benzylidene-4,6-pyrimidinediones. Eur J Med Chem 45:16671672. doi:http://dx.doi.org/10.1016/j.ejmech.2009.12.030

Web End =10.1016/j.ejmech.2009.12.030

36. Zidar N, Tomasic T, Sink R, Rupnik V, Kovac A, Turk S, Patin D, Blanot D, Contreras Martel C, Dessen A, Mueller-Premru M, Zega A, Gobec S, Peterlin Masic L, Kikelj D (2010) Discovery of novel 5-benzylidenerhodanine and 5-benzylidenethiazolidine-2,4-dione inhibitors of MurD ligase. J Med Chem 53:65846594. doi:http://dx.doi.org/10.1021/jm100285g

Web End =10.1021/jm100285g

37. Zidar N, Tomai T, ink R, Kova A, Patin D, Blanot D, Contreras-Martel C, Dessen A, Mueller-Premru M, Zega A, Gobec S, Mai LP, Kikelj D (2011) New 5-benzylidenethiazolidin-4-one inhibitors of bacterial MurD ligase: design, synthesis, crystal structures, and biological evaluation. Eur J Med Chem 46:55125523. doi:http://dx.doi.org/10.1016/j.ejmech.2011.09.017

Web End =10. http://dx.doi.org/10.1016/j.ejmech.2011.09.017

Web End =1016/j.ejmech.2011.09.017

38. Chen H, Fan Y-H, Natarajan A, Guo Y, Iyasere J, Harbinski F, Luis L, Christ W, Aktas H, Halperin J (2004) Synthesis and biological evaluation of thiazolidine-2,4-dione and 2,4-thione derivatives as inhibitors of translation initiation. Bioorg Med Chem Lett 14:5401 5405. doi:http://dx.doi.org/10.1016/j.bmcl.2004.08.017

Web End =10.1016/j.bmcl.2004.08.017

39. Whitesitt CA, Simon RL, Reel Jon K, Sigmund SK, Phillips ML, Shadle JK, Heinz LJ, Koppel GA, Hundel DC, Lifer SL, Berry D, Ray J, Little SP, Liu X, Marshall W (1996) Synthesis and structureactivity relationships of benzophenones as inhibitors of cathepsin D. Bioorg Med Chem Lett 6:21572162.doi:http://dx.doi.org/10.1016/0960-894X(96)00393-9

Web End =10.1016/ http://dx.doi.org/10.1016/0960-894X(96)00393-9

Web End =0960-894X(96)00393-9

40. Lee B, Jung ME, Wolf MC, Zhang T, Patent WO 2010/044924, 22 April 2010. Demande PCT/US 2009/047854, 18 June 2009

41. Opletalova V, Dolezel J, Kralova K, Pesko M, Kunes J, Jampilek J (2011) Synthesis and characterization of (Z)-5-arylmethylidenerhodanines with photosynthesis-inhibiting properties. Molecules 16:52075227. doi:http://dx.doi.org/10.3390/molecules16065207

Web End =10.3390/molecules16065207

42. Alizadeh A, Khodaei MM, Eshghi A (2010) A solvent-free protocol for the green synthesis of arylalkylidene rhodanines in a task-specic ionic liquid. Can J Chem 88:514518. doi:http://dx.doi.org/10.1139/V10-011

Web End =10.1139/ http://dx.doi.org/10.1139/V10-011

Web End =V10-011

43. Gong K, He ZW, Xu Y, Fang D, Liu Z-L (2008) Green synthesis of 5-benzylidene rhodanine derivatives catalyzed by 1-butyl-3-methyl imidazolium hydroxide in water. Monatsh Chem 139:913 915. doi:http://dx.doi.org/10.1007/s00706-008-0871-y

Web End =10.1007/s00706-008-0871-y

44. Ben-Alloum A, Bakkas S, Bougrin K, Souaoui M (1998) Synthse de nouvelles spiro-rhodanine-pyrazolines par addition dipolaire-1,3 de la diphenylnitrilimine sur quelques 5-arylidnerhodanines en milieu sec et sous irradiation micro-onde. New J Chem 22:809 812. doi:http://dx.doi.org/10.1039/A803447H

Web End =10.1039/A803447H

45. Sing WT, Lee CL, Yeo SL, Lim SP, Sim MM (2001) Arylalkylidene rhodanine with bulky and hydrophobic functional group as selective HCV NS3 protease inhibitor. Bioorg Med Chem Lett 11:9194. doi:http://dx.doi.org/10.1016/S0960-894X(00)00610-7

Web End =10.1016/S0960-894X(00)00610-7

46. Altomare A, Burla MC, Camalli M, Cascarano G, Giacovazzo C, Guagliardi A, Moliterni AGG, Polidori G, Spagna R (1999) SIR97: a new tool for crystal structure determination and renement. J Appl Cryst 32:115119. doi:http://dx.doi.org/10.1107/S0021889898007717

Web End =10.1107/S0021889898007717

47. Sheldrick GM (2008) A short history of SHELX. Acta Cryst A64:112122. doi:http://dx.doi.org/10.1107/S0108767307043930

Web End =10.1107/S0108767307043930

48. Farrugia LJ (1999) WinGX suite for small-molecule single-crystal crystallography. J Appl Cryst 32:837838. doi:http://dx.doi.org/10.1107/S0021889899006020

Web End =10.1107/ http://dx.doi.org/10.1107/S0021889899006020

Web End =S0021889899006020

49. van der Sluis P, Spek AL (1990) BYPASS: an effective method for the renement of crystal structures containing disordered solvent regions. Acta Cryst A46:194201. doi:http://dx.doi.org/10.1107/S0108767389011189

Web End =10.1107/ http://dx.doi.org/10.1107/S0108767389011189

Web End =S0108767389011189

50. Spek AL (2003) Single-crystal structure validation with the program PLATON. J Appl Cryst 36:713. doi:http://dx.doi.org/10.107/S0021889802022112

Web End =10.107/ http://dx.doi.org/10.107/S0021889802022112

Web End =S0021889802022112

51. Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, Greengard P, Biernat J, Mandelkow E-M, Eisenbrand G, Meijer L (2001) Indirubins inhibit glycogen synthase kinase-3 and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimers disease: a property common to most cyclin-dependant kinase inhibitors? J Biol Chem 276:251260. doi:http://dx.doi.org/10.1074/jbc.M002466200

Web End =10.1074/jbc.M002466200

52. Primot A, Baratte B, Gompel M, Borgne A, Liabeuf S, Romette JL, Costantini F, Meijer L (2000) Purication of GSK-3 by afnity chromatography on immobilized axin. Protein Expr Purif 20:394 404. doi:http://dx.doi.org/10.1006/prep.2000.1321

Web End =10.1006/prep.2000.1321

53. Reinhardt J, Ferandin Y, Meijer L (2007) Purication of CK1 by afnity chromatography on immobilised axin. Protein Expr Purif 54:101109. doi:http://dx.doi.org/10.1016/j.pep.2007.02.020

Web End =10.1016/j.pep.2007.02.020

123